An interdisciplinary approach at the University of Illinois enabled researchers to combine 3D printing and stem cells to create “biobots”. A “biobot” is defined as a biological machine; in this case it was made with hydrogel, heart stem cells, and a 3D printer. In a scene reminiscent of the 1966 sci-fi movie ‘The Fantastic Voyage’ the research points to the development of small [tiny] ‘biobots’ that could travel within the body identifying cancers or toxins and enabling precision delivery of drugs or other treatments.
To learn more about the utility of stem cells, how regenerative medicine is shaping the future of medicine, how you can safely preserve your own stem cells to use in emerging regenerative therapies and ensure your family’s future health, visit www.StemSave.com or call 877-783-6728 (877-StemSave) today.
Dr. Ganesh Raveendran, MD, MS, Director, Cardiac Catheterization Laboratory at the University of Minnesota Medical Center is conducting a clinical study using autologous [the patient’s own] stem cells to treat patients requiring Left-Ventricular Assist Devices (LVADs). The clinical study hopes to create a viable alternative for patients that might otherwise require a complete heart transplant. According to Dr. Raveendran, “there are only 2,500 heart transplants done annually in this country [USA], whereas more than 100,000 patients are waiting to get heart transplants. So there is a gap between patients who need hearts and the number of patients who can get hearts.” The success of the treatment would eliminate the need for many heart transplants and provide a viable alternative to individuals awaiting a heart transplant [where there is a shortage of hearts].
The Mayo Clinic, which has been involved in stem cell research and prospective therapies for two decades, reports that we are at the threshold of a medical revolution. By using the body’s own ability to repair and maintain itself, researchers will be able to treat and, in many cases cure, many of today’s most intractable medical conditions. As Dr. Brooks Edwards of the Mayo Clinic explains, “we’re not going to need to wait for a tragic accident and a young person to donate a heart or a liver or a kidney. We’re going to be regenerating those organs. So then if I’m on a transplant list … I’ll be using my cells or some kind of cell-based therapy to either strengthen my own heart, or regenerate my own heart, or even grow a new heart.” Dr. Edwards goes on to predict that solid organ transplants — say, a liver grown from a patient’s own cells — will take place within a decade.
Researchers at the University of Toronto, led by Milica Radisic, Canada Research Chair in Functional Cardiovascular Tissue Engineering and Associate Professor at the Institute of Biomaterials & Biomedical Engineering (IBBME) and the Department of Chemical Engineering, have developed a multidisciplinary technique for maturing human heart cells. The new technique, referred to as “biowire,” enables scientists to differentiate stem cells into beating cardiomyocites in vitro [outside the body]. Researchers envision utilizing the technique to create cardiac patches for transplantation to replace damaged tissue for those suffering from heart failure. Heart disease is the leading cause of death in the United States.
Researchers at Mayo Clinic have introduced a new therapy using cardiogenically-instructed stem cells that can improve heart health. This is the first clinical study for the targeted regeneration of a failing organ. The Mayo Clinic study represents what we believe to be the gold standard in regenerative treatments – utilizing the patient’s own stem cells for the therapy. As a result of the use of autologous [the patient’s own] stem cells, there were no complications in any of the patients. Every patient in the stem cell treatment group improved. “The benefit to patients who received cardiopoietic stem cell therapy was significant,” said Dr. Terzic – the senior author of the study, with improvements in heart pumping function, physical performance (such as walking distance) and overall quality of life.
Hypoxic-Ischemic brain injury can be caused by a number of ailments including cardiac arrest (heart attack), respiratory arrest, incomplete suffocation and more. The incidence in the United States of hypoxic-ischemic brain injuries is 1-8 in every 1000 births. Researchers at Nagoya University have used stem cells from human exfoliated deciduous teeth (SHED) to treat neonatal mice with hypoxic-ischemic brain injuries. They have found that this treatment leads to neurological and pathophysiological recovery of these injuries. These finding indicate that SHED may be utilized in the future for a novel neuroprotective therapy for hypoxic-ischemic brain injuries. Continue reading →
Mesoblast, a leading stem cell technology and regenerative therapeutics company, received FDA approval to begin a Phase III clinical trial utilizing their stem cell therapy [Revascor] to treat heart failure. We have reported on Mesoblast in previous posts; most recently, the announcement that they were developing neural related regenerative therapies utilizing dental pulp stem cells.
Heart surgeons around the world are exploring the benefits of using stem cell therapies in conjunction with major surgical procedures as a means of increasing efficacy. Dr Mukesh Hariawala of Mumbai’s Jaslok Hospital will conduct the first of a new ‘triple therapy’ for bypass patients in early 2013. This ‘natural’ bypass therapy involves of a combination of angiogenesis, stem cell therapy, and a bypass surgery to treat progressive heart conditions.
In a recent Phase I clinical study, a collaboration of the Cedars-Sinai Heart Institute, the EMMES Corporation and Johns Hopkins University, researchers sought to regenerate heart tissue that is functionally compromised and typically scarred as a result of a heart attack. More specifically, the treatment involves the extraction of the stem cells from the patients, the in vitro [in the lab] expansion of the stem cells and the transplantation of the stem cells back into the patient. The success of this early stage study should lead the way to larger larger studies.
The FDA has approved Phase II clinical trials for an autologous [utilizing the patient’s own stem cells] stem cell treatment for heart attacks – the leading cause of death for both men and women in the United States. The treatment involves the extraction of the stem cells from the patient, the in vitro [in the lab] expansion and differentiation of the stem cells and the transplantation of the stem cells back into the patient. This is a very significant clinical trial as we believe it represents the gold standard of emerging stem cell treatments – the use of autologous stem cells which are then expanded, differentiated and transplanted to address disease, trauma and injury. As we have reported recently, this same approach is being used to grow entire organs which are then successfully transplanted back into the patient. This approach facilitates the safe and successful application of stem cell therapies as it eliminates the chance of rejection and does away with the need for the patient to take a cocktail of immuno-suppression drugs.